Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 27,000 shares of the firm's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $21.23, for a total value of $573,210.00. Following the sale, the insider owned 115,743 shares of the company's stock, valued at $2,457,223.89. The trade was a 18.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Adam Crystal also recently made the following trade(s):
- On Wednesday, April 15th, Adam Crystal sold 38,460 shares of Tango Therapeutics stock. The shares were sold at an average price of $25.00, for a total value of $961,500.00.
- On Wednesday, April 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $21.20, for a total transaction of $572,400.00.
- On Wednesday, March 25th, Adam Crystal sold 12,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $20.11, for a total transaction of $241,320.00.
- On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The shares were sold at an average price of $15.00, for a total transaction of $303,765.00.
- On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The shares were sold at an average price of $12.77, for a total transaction of $693,985.65.
Tango Therapeutics Stock Up 6.6%
TNGX stock opened at $24.20 on Wednesday. Tango Therapeutics, Inc. has a 12-month low of $1.03 and a 12-month high of $28.41. The company has a market cap of $3.49 billion, a price-to-earnings ratio of -27.82 and a beta of 1.22. The company has a 50 day moving average of $19.74 and a two-hundred day moving average of $13.44.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. On average, research analysts anticipate that Tango Therapeutics, Inc. will post -1.35 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the company. Mizuho raised their price target on Tango Therapeutics from $19.00 to $20.00 and gave the stock an "outperform" rating in a research note on Wednesday, March 11th. Stifel Nicolaus boosted their price target on Tango Therapeutics from $24.00 to $40.00 and gave the company a "buy" rating in a research note on Monday, April 27th. Canaccord Genuity Group started coverage on shares of Tango Therapeutics in a research report on Thursday, April 2nd. They set a "buy" rating and a $30.00 price objective on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Tango Therapeutics in a research note on Monday, April 20th. Finally, Wall Street Zen downgraded shares of Tango Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $22.44.
Read Our Latest Report on TNGX
Institutional Trading of Tango Therapeutics
Several large investors have recently made changes to their positions in the stock. Bleakley Financial Group LLC bought a new stake in shares of Tango Therapeutics during the 1st quarter worth about $259,000. Candriam S.C.A. raised its stake in shares of Tango Therapeutics by 79.1% in the 1st quarter. Candriam S.C.A. now owns 1,269,246 shares of the company's stock valued at $26,553,000 after acquiring an additional 560,434 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Tango Therapeutics by 10.2% in the 1st quarter. SG Americas Securities LLC now owns 24,257 shares of the company's stock worth $507,000 after purchasing an additional 2,251 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in Tango Therapeutics in the 4th quarter worth approximately $1,906,000. Finally, XTX Topco Ltd bought a new stake in Tango Therapeutics during the fourth quarter worth approximately $335,000. Institutional investors own 78.99% of the company's stock.
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.
The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
